secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0001615219-24-000019
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharma gets Nasdaq extension to Sep 3 for bid price compliance; will pursue reverse split if needed
--------------------------------------------------------------------------------

- Nasdaq granted Salarius until Sep 3, 2024 to regain $1.00 minimum bid price compliance.
- Bid price must close at or above $1.00 for 10 consecutive business days by September 3.
- Company notified Nasdaq it will seek a reverse stock split if necessary to meet the requirement.
- Failure to regain compliance by Sep 3 could lead to delisting notice and appeal process.
- September 2023 non-compliance letter gave until March 4, 2024; extension now granted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000019/0001615219-24-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521924000019/flks-20240305.htm
  HTML page:      https://secwatch.observer/filing/0001615219-24-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer